Evidence map›Paper›PMID 24553769›Full record

ReviewDer Internist2014

[Induced pluripotent stem cells. A new resource in modern medicine].

S Liebau, M Stockmann, A Illing, T Seufferlein, A Kleger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

S LiebauInstitut für Neuroanatomie, Eberhard Karls Universität Tübingen, Österbergstr. 3, 72074, Tübingen, Deutschland, stefan.liebau@uni-tuebingen.de.
M Stockmann
A Illing
T Seufferlein
A Kleger

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pluripotent stem cells possess a remarkable unlimited self-renewal capacity and offer unparalleled in vitro differentiation potential. This provides a unique model system not only to study early human development but also gives renewed hope in terms of developing cell therapies and regenerative medicine. S. Yamanaka, a medical doctor and researcher, reported the possibility of reprogramming somatic cells to so-called induced pluripotent stem cells via the ectopic expression of four transcription factors, namely Oct4, Sox2, Klf4 and c-Myc. This Nobel Prize winning work has since revolutionized stem cell research and paved the way for countless new avenues within regenerative medicine. This includes disease modeling in a patient-specific context with the ultimate aim of individually tailored pharmaceutical therapy. Additionally, genetic correction studies have rapidly increased in basic science and thus there is hope that these can be effectively and efficiently translated into clinical applications. Addressing the medical community this review gives a broad general overview about the state of the research field and possible clinical applications of pluripotent stem cells.

Indexed as

Amyotrophic Lateral SclerosisCell- and Tissue-Based TherapyCell DifferentiationCooperative BehaviorEmbryonic Stem CellsGene ExpressionGenetic TherapyGene Transfer TechniquesHumansInterdisciplinary CommunicationKruppel-Like Factor 4Kruppel-Like Transcription FactorsMutationOctamer Transcription Factor-3Parkinson DiseasePluripotent Stem CellsKLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription FactorsMYC protein, humanOctamer Transcription Factor-3POU5F1 protein, humanProto-Oncogene Proteins c-mycSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.